Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2025 14:41 ET | Source: Fight Colorectal Cancer

First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients

Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) -- First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine,...
June 05, 2025 08:00 ET | Source: CG Oncology Inc.

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
June 04, 2025 16:01 ET | Source: Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...
June 03, 2025 09:10 ET | Source: Trethera Corporation

Trethera Secures New License, Strengthening TRE-515 Intellectual Property Portfolio and Extending Market Exclusivity to 2045

Global exclusive agreement expands patent coverage for compound structures and autoimmune uses across major pharmaceutical markets
June 02, 2025 16:05 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of...
June 02, 2025 10:30 ET | Source: 4D Path

4D Path Presents Breakthrough Research Demonstrating That Its Unique Digital Predictive Biomarker Identifies Treatment Responders in a Difficult-To-Treat Breast Cancer Patient Population

4D Path QPORTM platform delivers unprecedented predictive insights for patients with low immune infiltrates—achieving a 66% response rate
June 02, 2025 10:00 ET | Source: Precede Biosciences, Inc.

Precede Biosciences Presents ASCO 2025 Data Highlighting the Ability of its Liquid Biopsy Platform to Reveal the Biology Underlying Response and Resistance to ADCs and Radiopharmaceuticals

Using just 1mL of plasma, the Precede Bio platform identified key molecular pathways linked to response and resistance in patients with metastatic breast and prostate cancer treated with sacituzumab...
June 02, 2025 09:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual...
June 02, 2025 09:00 ET | Source: IGI, Inc.

Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma

Ichnos Glenmark Innovation presented full results of TRIgnite-1 study of ISB 2001 at ASCO showing continued high response rate and favorable safety profile
June 02, 2025 08:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing...

Next Page keyboard_arrow_right